The aim is to comparatively study Shugan Jieyu capsule and sertraline for non-inferiority in the treatment of patients with acute myocardial infarction and depression (observing the curative effects and safety) by the randomized controlled experiment.
Methods
A total of 149 patients with acute myocardial infarction and depression were randomly divided into two groups, the Shugan Jieyu group (76 cases) and the sertraline group (73 cases), and received treatments for 24 weeks. Depression states were assessed by the rote diagnostic checklist, and effects were evaluated by the Hamilton depression scale. Drug safety for heart was assessed by left ventricular ejection fraction (reduced by 5%), blood pressure, heart rate, P-wave and R wave interval, Q-R-S complex wave, and corrected Q-T interval after 12 weeks of treatment.
Results
There were no significant differences in the effective rates of Shugan Jieyu and sertraline groups. Significantly lower adverse event rate was observed in the Shugan Jieyu group. Two groups had a similar cardiac safety.
Conclusion
Shugan Jieyu capsule has a reliable effect and high safety in patients with acute myocardial infarction and depression.
GlassmanAHShapiroPA. Depression and the course of coronary artery disease. Am J Psychiatry1998; 155: 4–11.
2.
AriyoAAHaanMTangenCM. Cardiovascular Health Study Collaborative Research Group. Depressive symptoms and risks of coronary heart disease and mortality in elderly Americans. Circulation2000; 102: 1773–1779.
3.
SchulzRBeachSRIvesDG. Association between depression and mortality in older adults: the Cardiovascular Health Study. Arch Intern Med2000; 160: 1761–1768.
4.
AromaaARaitasaloRReunanenA. Depression and cardiovascular diseases. Acta Psychiatr Scand1994; 89: 77–82.
5.
FordDEMeadLAChangPP. Depression is a risk factor for coronary artery disease in men: the precursors study. Arch Intern Med1998; 158: 1422–1426.
6.
CarneyRMRichMWFreedlandKE. Major depressive disorder predicts cardiac events in patients with coronary artery disease. Psychosom Med1988; 50: 627–633.
7.
LespéranceFFrasure-SmithNJuneauM. Depression and 1-year prognosis in unstable angina. Arch Intern Med2000; 160: 1354–1360.
8.
WelinCLappasGWilhelmsenL. Independent importance of psychosocial factors for prognosis after myocardial infarction. J Intern Med2000; 247: 629–639.
9.
JiangWAlexanderJChristopherE. Relationship of depression to increased risk of mortality and rehospitalization in patients with congestive heart failure. Arch Intern Med2001; 161: 1849–1856.
10.
KoenigHG. Depression in hospitalized older patients with congestive heart failure. Gen Hosp Psychiatry1998; 20: 29–43.
11.
GlassmanAHRooseSPBiggerJTJr. The safety of tricyclic antidepressants in cardiac patients. Risk-benefit reconsidered. JAMA1993; 269: 2673–2675.
12.
GlassmanAHO’ConnorCMCaliffRM. Sertraline Antidepressant Heart Attack Randomized Trial (SADHEART) Group. Sertraline treatment of major depression in patients with acute MI or unstable angina. JAMA2002; 288: 701–709.
13.
TangYH. Hamilton depression rating scale. Shanghai Spirit Med1984; 2: 61–64.
14.
ZhuCH. Braunwald cardiology, 6th ed. Beijing, China: People’s Health Publishing House, 2007, pp. 1648–1651.
15.
ZhangXLDingFMZhuYW. Study about the effect of depression on heart rate variability in patients with PCI after STEMI. Hebei Med2009; 15: 1009–1012.
16.
ChenY. The relationship between depression and the decrease of cardiac reflex regulation in coronary heart disease. Foreign Med Sci Sect Cardiovasc Dis2000; 27: 53.
17.
LindeKBernerMMKristonL. St. John’s wort for major depression. Cochrane Database Syst Rev2008; 2008: CD000448.
18.
LiSQLuoHS. Chinese medicine were discussed from the role of acanthopanax “volition”. Chin J Basic Med2000; 6: 9–11.
19.
SongWZYangXLWeiML. Efficacy and safety of Shugan Jieyu capsules in treatment of mild or moderate depression. World Clinic Drugs2015; 36: 696–699.
20.
FuJZhangYWuR. Shugan Jieyu capsule increases neurotrophic factor expression in a rat model of depression. Neural Regeneration Research2014; 9: 489–497.
21.
ZhuXW. Progress in research on Peach Hypericum perfortum II and clinical application of pharmacokinetics, pharmacodynamics. Foreign Pharmaceut Plant Med Branch1998; 13: 153–156.
22.
NieWZhangYXZhouJH. Research and prospect on the antidepressant effect of the extract of the golden peach. Chin J Exp Med2001; 7: 59–61.
23.
KalbRTrautmann-SponselRDKieserM. Efficacy and tolerability of hypericum extract WS 5572 versus placebo in mildly to moderately depressed patients. A randomized double-blind multicenter clinical trial. Pharmacopsychiatry2001; 34: 96–103.
24.
UebelhackRGruenwaldJGraubaumHJ. Efficacy and tolerability of Hypericum extract STW 3-VI in patients with moderate depression: a double-blind, randomized, placebo-controlled clinical trial. Adv Ther2004; 21: 265–275.
25.
SzegediAKohnenRDienelA. Acute treatment of moderate to severe depression with hypericum extract WS 5570 (St John’s wort): randomised controlled double blind non-inferiority trial versus paroxetine. BMJ2005; 330: 503–506.
26.
GastparMSingerAZellerK. Efficacy and tolerability of hypericum extract STW3 in long-term treatment with a once-daily dosage in comparison with sertraline. Pharmacopsychiatry2005; 38: 78–86.
27.
MurckHFavaMAlpertJ. Hypericum extract in patients with MDD and reversed vegetative signs: re-analysis from data of a double-blind, randomized trial of hypericum extract, fluoxetine, and placebo. Int J Neuropsychopharmacol2005; 8: 215–221.
28.
FavaMAlpertJNierenbergAA. A Double-blind, randomized trial of St John’s wort, fluoxetine, and placebo in major depressive disorder. J Clin Psychopharmacol2005; 25: 441–447.
29.
BjerkenstedtLEdmanGVAlkenRG. Hypericum extract LI160 and fluoxetine in mild to moderate depression: a randomized, placebo-controlled multicenter study in outpatients. Eur Arch Psychiatry Clin Neurosci2005; 255: 40–47.
30.
LindeKBernerMEggerM. St John’s wort for depression: meta-analysis of randomised controlled trials. Br J Psychiatry2005; 186: 99–107.
